Anticoagulant and Antiplatelet Therapy for Post-CABG Patients with Atrial Fibrillation

Patient Risk Factors and Assessment

The European Society of Cardiology recommends lifelong oral anticoagulation for patients with persistent atrial fibrillation to prevent stroke and thromboembolism 1
Barrett's esophagus increases the risk of gastrointestinal bleeding, which should be considered when selecting anticoagulation, according to the American College of Chest Physicians 2, 3
The use of pantoprazole provides some protection against gastrointestinal bleeding, as suggested by the American College of Chest Physicians 4
Recent CABG with atrial clip is considered cardiac surgery, as stated by the American College of Cardiology 5

The European Society of Cardiology recommends a direct oral anticoagulant (DOAC) as the preferred anticoagulant over vitamin K antagonists (VKAs) like warfarin due to lower risk of major, fatal, and intracranial bleeding while maintaining efficacy for stroke prevention 1, 6
The standard dose of the selected DOAC should be used unless specific dose-reduction criteria are met, according to the European Society of Cardiology 1

The European Society of Cardiology does not recommend adding antiplatelet therapy to oral anticoagulation for patients at 4 weeks post-CABG 1, 4
For patients with atrial fibrillation and stable coronary artery disease, oral anticoagulation monotherapy is preferred over combination therapy with aspirin, as suggested by the American College of Chest Physicians 4, 7

The CHA2DS2-VASc score should be used to assess stroke risk, according to the American College of Chest Physicians 2, 8
The HAS-BLED score should be used to assess bleeding risk, and if the score is ≥3, more regular review and follow-up is needed, as recommended by the American College of Chest Physicians 2, 8
Barrett's esophagus should be factored into the bleeding risk assessment, according to the American College of Chest Physicians 2, 4

The patient's recent CABG with atrial clip does not change the recommendation for anticoagulation, as surgical left atrial appendage occlusion is considered an adjunct to, not a replacement for, oral anticoagulation, according to the European Society of Cardiology 1, 5

Underdosing DOACs should be avoided unless specific criteria for dose reduction are met, as recommended by the European Society of Cardiology 1
Adding antiplatelet therapy to oral anticoagulation without a clear indication should be avoided, as it significantly increases bleeding risk without additional benefit for stroke prevention, according to the European Society of Cardiology and the American College of Chest Physicians 1, 4